HIV/AIDS Therapy

Viramune or Efavirenz regimens demonstrate comparable viral decay rate

Published in AIDS Weekly, October 13th, 2003

A sub-study of the landmark 2NN trial found that HIV treatment regimens containing either Viramune (nevirapine) or efavirenz provide a comparable viral decay rate (VDR) over the first 2 weeks of treatment.

The VDR measures the decline in viral load concentration after the start of therapy. Additionally, virologic failure after 48 weeks in patients treated with the drugs was shown to be unrelated to a higher VDR. The results of the sub-study were presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy.

"The results of this 2NN sub-study offer further evidence of the comparable virologic efficacy of Viramune and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2003-10-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry